Trial Profile
Efficacy of atorvastatin (10 and 80 mg/day) in patients with stable coronary disease
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 Aug 2021
Price :
$35
*
At a glance
- Drugs Atorvastatin (Primary)
- Indications Coronary artery disease
- Focus Pharmacogenomic; Therapeutic Use
- Acronyms TNT
- Sponsors Pfizer
- 26 Jun 2021 Results of pooled post-hoc analysis of two studies (IDEAL, NCT00159835 and TNT, NCT00327691) were presented at The International Liver Congress 2021.
- 05 Apr 2018 Results (n=4853) of analysis estimating individual benefit from PCSK9 inhibition in terms of months gained free of stroke or MI in statin treated patients with stable CAD published in the Heart
- 04 Apr 2018 Results of post-hoc analysis assessing the relationship between TRL-C and cardiovascular risk, and whether this risk was modifiable among patients receiving statins in the TNT trial published in the Circulation